Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...
Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...
Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment ...
Investor's Business Daily on MSN
Why Merck might have a fight on its hands with its $6.7 billion takeover of Terns
Merck made plans Wednesday to beef up its cancer treatment portfolio with the $6.7 billion acquisition of Terns Pharmaceuticals.
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
Which medicine is best when you are affected by cancer? This can vary from person to person. A new method can help people with a specific type of blood cancer get the best medicine for them. "The new ...
Treatment-free remission (TFR) may be feasible in many patients with chronic myeloid leukaemia (CML), say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase ...
A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3 + regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results